View Post

Breast Cancer Drug Available on CDF

In In The News by Barbara Jacoby

A potentially life-extending drug combination for some people with advanced breast cancer will be made available on England’s Cancer Drugs Fund (CDF) following a recommendation by the National Institute for Health and Care Excellence (NICE). The draft guidance recommended ribociclib (Kisqali, Novartis) with fulvestrant (Faslodex, AstraZenica) as an option for people with hormone receptor-positive, human epidermal growth factor receptor 2 …

View Post

Drug Combination May Improve Impact of Immunotherapy in Head and Neck Cancer

In In The News by Barbara Jacoby

From: UCSD Health Communications Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy’s effectiveness. In a paper published in the journal JCI Insights on September …